Cargando…

Cell-free DNA in non-small cell lung cancer

Lung cancer is the leading cause of cancer-associated deaths worldwide. Surgery is the standard treatment for early-stage non-small cell lung cancer (NSCLC). Advances in the knowledge of the biology of non-small cell lung cancer have revealed molecular information used for systemic cancer therapy ta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gedvilaitė, Vaida, Schveigert, Diana, Cicėnas, Saulius
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lithuanian Academy of Sciences Publishers 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566953/ https://www.ncbi.nlm.nih.gov/pubmed/28845132 http://dx.doi.org/10.6001/actamedica.v24i2.3495

Ejemplares similares

Lung Cancer Survival in Lithuania: Changes by Histology, Age, and Sex From 2003-2007 to 2008-2012
por: Gedvilaitė, Vaida, et al.
Publicado: (2019)

Surveillance of cfDNA Hot Spot Mutations in NSCLC Patients during Disease Progression
por: Sestokaite, Agne, et al.
Publicado: (2023)

Lung cancer in patients with tuberculosis
por: Cicėnas, Saulius, et al.
Publicado: (2007)

Non-pulmonary cancer risk following tuberculosis: a nationwide retrospective cohort study in Lithuania
por: Everatt, Ruta, et al.
Publicado: (2017)

Dynamics of methylated cell-free DNA in the urine of non-small cell lung cancer patients
por: Bach, Sander, et al.
Publicado: (2021)

Clinical significance of plasma free DNA in patients with non-small cell lung cancer
por: Ma, Lanxiang, et al.
Publicado: (2019)

Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer
por: Kapeleris, Joanna, et al.
Publicado: (2022)

Quantification of circulating cell-free DNA to predict patient survival in non-small-cell lung cancer
por: Hyun, Myung Han, et al.
Publicado: (2017)

Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer
por: Ai, Bo, et al.
Publicado: (2016)

Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials
por: Eide, Inger Johanne Zwicky, et al.
Publicado: (2022)

A Cohort Study of Exposure to Antihyperglycemic Therapy and Survival in Patients with Lung Cancer
por: Danila, Edvardas, et al.
Publicado: (2020)

Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease
por: Szpechcinski, A, et al.
Publicado: (2015)

Serum circulating cell free DNA as potential diagnostic and prognostic biomarker in non small cell lung cancer
por: Soliman, Shimaa El-Shafey, et al.
Publicado: (2018)

Urine cell‐free DNA as a promising biomarker for early detection of non‐small cell lung cancer
por: Ren, Sai, et al.
Publicado: (2020)

Plasma cell-free DNA and survival in non-small-cell lung cancer: A meta-analysis
por: Yi, Zongbi, et al.
Publicado: (2017)

Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients
por: Janke, Florian, et al.
Publicado: (2022)

Individual and combined effect of TP53, MDM2, MDM4, MTHFR, CCR5, and CASP8 gene polymorphisms in lung cancer
por: Stumbryte, Ausra, et al.
Publicado: (2017)

Spontaneous pneumothorax as a first sign of pulmonary carcinoma
por: Vencevičius, Vladislavas, et al.
Publicado: (2009)

5-Hydroxymethylome in Circulating Cell-free DNA as A Potential Biomarker for Non-small-cell Lung Cancer
por: Zhang, Ji, et al.
Publicado: (2018)

Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients
por: Kageyama, Shun-ichiro, et al.
Publicado: (2018)

Predicting tumour content of liquid biopsies from cell-free DNA
por: Cardner, Mathias, et al.
Publicado: (2023)

A quantitative analysis of the potential biomarkers of non-small cell lung cancer by circulating cell-free DNA
por: Wei, Lirong, et al.
Publicado: (2018)

Gene and miRNA expression profiles of mouse Lewis lung carcinoma LLC1 cells following single or fractionated dose irradiation
por: Stankevicius, Vaidotas, et al.
Publicado: (2017)

Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients – initial observations
por: Nygård, Lotte, et al.
Publicado: (2020)

Genomic Alteration Spectrum of Non-Small Cell Lung Cancer Patients in East-China Characterized by Tumor Tissue DNA and Cell-Free DNA
por: Li, Jie, et al.
Publicado: (2022)

Aberrant Methylation of SLIT2 Gene in Plasma Cell-Free DNA of Non-Small Cell Lung Cancer Patients
por: Kim, Yujin, et al.
Publicado: (2022)

Tumor volume determines the feasibility of cell‐free DNA sequencing for mutation detection in non‐small cell lung cancer
por: Ohira, Tatsuo, et al.
Publicado: (2016)

Tumor volume as a predictor of cell free DNA mutation detection in advanced non-small cell lung cancer
por: Haseltine, Justin M., et al.
Publicado: (2022)

Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer
por: Veldore, Vidya H, et al.
Publicado: (2018)

Interventional pulmonology use of cell-free DNA assay for metastatic non–small cell lung cancer: the UC Davis experience
por: Phan, Chinh, et al.
Publicado: (2022)

Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer
por: Sivapalan, Lavanya, et al.
Publicado: (2023)

Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non‐small‐cell lung cancer treated with pembrolizumab
por: Mondelo‐Macía, Patricia, et al.
Publicado: (2021)

Comparative analysis of TTF‐1 binding DNA regions in small‐cell lung cancer and non‐small‐cell lung cancer
por: Hokari, Satoshi, et al.
Publicado: (2019)

Correction: Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients
por: Kageyama, Shun-Ichiro, et al.
Publicado: (2018)

The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management
por: Fernandes, Maria Gabriela O., et al.
Publicado: (2021)

Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma
por: Raman, Lennart, et al.
Publicado: (2020)

Cell-Free DNA at Diagnosis for Stage IV Non-Small Cell Lung Cancer: Costs, Time to Diagnosis and Clinical Relevance
por: Koole, Simone N., et al.
Publicado: (2022)

Quantification of Cell-Free mSHOX2 Plasma DNA for Therapy Monitoring in Advanced Stage Non-Small Cell (NSCLC) and Small-Cell Lung Cancer (SCLC) Patients
por: Schmidt, Bernd, et al.
Publicado: (2015)

Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)
por: Agulnik, Jason S., et al.
Publicado: (2022)

Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab
por: Alama, Angela, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9acuj6q6ubmq9n4o5bd2bigt0r